WinPro: Prospective Evaluation of pH-impedance Tracings According to the Wingate Consensus, and Influence on GERD Classification According to the Lyon Consensus

Sponsor
Universitair Ziekenhuis Brussel (Other)
Overall Status
Recruiting
CT.gov ID
NCT06084572
Collaborator
(none)
80
2
30.1
40
1.3

Study Details

Study Description

Brief Summary

Commonly, in clinical practice an automated analysis of pH-MII tracings is obtained.

Condition or Disease Intervention/Treatment Phase
  • Other: Questionnaires

Detailed Description

All pH-MII performed in UZ Brussel are already reviewed manually according to the Wingate con-sensus and interpreted according to the Lyon consensus. In this study, we will prospectively catego-rise the reasons for discarding reflux episodes identified by automated analysis during the manual review according to the Wingate consensus, as well as the impact on different parameters related to the interpretation of pH-MII. Based on comments received to our retrospective study, we will eval-uate possible confounders to the interpretation, including the indication for referral for pH-MII, symptom severity, use of PPI during pH-MII.

Study Design

Study Type:
Observational
Anticipated Enrollment :
80 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Prospective Evaluation of pH-impedance Tracings According to the Wingate Consensus, and Influence on Gastro-oesophageal Reflux Disease (GERD) Classification According to the Lyon Consensus.
Actual Study Start Date :
Sep 29, 2023
Anticipated Primary Completion Date :
Apr 1, 2026
Anticipated Study Completion Date :
Apr 1, 2026

Arms and Interventions

Arm Intervention/Treatment
GERD patients

Other: Questionnaires
FSSG & BEDQ

Outcome Measures

Primary Outcome Measures

  1. Statistical difference in the GRED categorisation [During baseline visit]

    the statistical difference in the distribution of GERD categorisation between automated vs. manual review of the pH-MII tracings

Secondary Outcome Measures

  1. The analysis of the influence of different parameters on application of the Wingate criteria: including the Indication for referral with further classification into predominant oesophageal and extra-oesophageal symptoms; [During baseline visit]

  2. The analysis of the influence of different parameters on application of the Wingate criteria: including the GERD Symptom Severity; [During baseline visit]

  3. The analysis of the influence of different parameters on application of the Wingate criteria: including the patient being on or off PPI; [During baseline visit]

  4. The analysis of the influence of different parameters on application of the Wingate criteria: including MNBI (obtained by automated analysis or manually calculated); [During baseline visit]

  5. Presence of significant correlations between censored episodes and pH-MII parameters [During baseline visit]

    Correlations including: Acid exposure time; Total number of reflux episodes identified by impedance monitoring; MNBI; PSPWI.

  6. Impact of the Wingate criteria on The number of PSPW; [During baseline visit]

  7. Impact of the Wingate criteria on The number of symptoms associated with an impedance episode. [During baseline visit]

  8. Impact of the Wingate criteria on the number of impedance episodes with or without acidic reflux [During baseline visit]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Adult patients aged 18 - 80 years old;

  • pH-MII performed by Medtronic hardware.

Exclusion Criteria:
  • Prior upper GI endoscopy indicative of structural disease (except for oesophagitis or hiatal hernia).

  • Incomplete pH-MII (less than 21 hours recording);

  • Suboptimal quality of the tracings preventing interpretation in clinical practice;

  • Prior oesophageal (including anti-reflux intervention) or gastric surgery.

Contacts and Locations

Locations

Site City State Country Postal Code
1 UZ Brussel Brussel Brussels Belgium 1090
2 UZ Brussel Jette Belgium 1090

Sponsors and Collaborators

  • Universitair Ziekenhuis Brussel

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Universitair Ziekenhuis Brussel
ClinicalTrials.gov Identifier:
NCT06084572
Other Study ID Numbers:
  • WinPro
First Posted:
Oct 16, 2023
Last Update Posted:
Oct 16, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 16, 2023